- Angiotensin II type 2 receptor agonists: where should they be applied?
[作者:Verdonk, K; Danser, AHJ; van Esch, JHM,期刊:Expert opinion on investigational drugs, 页码:501-513 , 文章类型: Review,,卷期:2012年21-4]
- Introduction: Angiotensin II, the active endproduct of the renin-angiotensin system (RAS), exerts its effects via angiotensin II type 1 and type 2 (AT(1), AT(2)) receptors. AT(1) receptors mediate all well-known effects ...
- Sapacitabine for cancer
[作者:Liu, XJ; Kantarjian, H; Plunkett, W,期刊:Expert opinion on investigational drugs, 页码:541-555 , 文章类型: Editorial Material,,卷期:2012年21-4]
- Introduction: Sapacitabine is an orally bioavailable nucleoside analog prodrug that is in clinical trials for hematologic malignancies and solid tumors. The active metabolite of sapacitabine, CNDAC (2'-C-cyano-2'-deoxy-1...
- Sorafenib in melanoma
[作者:Mangana, J; Levesque, MP; Karpova, MB; Dummer, R,期刊:Expert opinion on investigational drugs, 页码:557-568 , 文章类型: Editorial Material,,卷期:2012年21-4]
- Introduction: Sorafenib is an orally available multi-kinase inhibitor that inhibits tumor proliferation by targeting multiple kinases including the vascular endothelial growth factor receptors VEGFR1, VEGFR2, VEGFR3 and ...
|